Market Cap (In USD)
199.32 Million
Revenue (In USD)
-
Net Income (In USD)
-99.91 Million
Avg. Volume
84.5 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 4.42-18.4
- PE
- -2.64
- EPS
- -1.48
- Beta Value
- -0.757
- ISIN
- CA29286M1059
- CUSIP
- -
- CIK
- 1100663
- Shares
- 50977560.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Ronald H. W. Cooper
- Employee Count
- -
- Website
- https://www.engene.com
- Ipo Date
- 2022-02-01
- Details
- enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
More Stocks
-
CTYLF
-
600420
-
DNTUYDentsu Group Inc.
DNTUY
-
VYBE
-
RTKM
-
605377
-
VOLCAR-BVolvo Car AB (publ.)
VOLCAR-B
-
088260E Kocref Cr-Reit
088260